Xinnate is a biopharmaceutical development company, co-founded by Helene Hartman and Artur Schmidtchen in 2019. The company is privately held and based in Lund, Sweden.

The company is built on more than 20 years of world class research by Professor Artur Schmidtchen and his team at Lund University. Working on understanding the natural healing process and why some wounds heal while others don’t, the team identified a group of multifunctional peptides derived from thrombin, known as TCPs, that play a critical role in regulating inflammation and promoting tissue repair, findings that have been published in leading scientific journals.

Xinnate operates in close cooperation with Professor Schmidtchen and his team with the aim to further develop and commercialize proprietary novel thrombin-derived peptides in the areas of wounds, inflammatory skin diseases, surgery and biomaterials.

Xinnate executes an ambitious clinical development program for TCP-25 Gel with a clear focus on patients with Epidermolysis bullosa (EB). The safety, tolerability and preliminary efficacy have been demonstrated in a completed phase 1 program which included healthy volunteers with induced wounds, patients with large complex wounds (VLU) and patients with Epidermolysis bullosa (EB) wounds. The next step will be a randomized controlled phase 2 study in EB-patients to further address the safety and efficacy of TCP-25 Gel.

The overarching strategy involves leveraging the TCP-25 platform to expand and develop a diverse portfolio of applications. The aim is to advance each concept to a stage where commercial deals with larger pharmaceutical companies possessing global presence can be achieved. These transactions may involve out-licensing, partnering, licensing, strategic partnerships, joint ventures, or the sale of assets.